| | | | Index Performance | | Index | Sensex | Nifty | | Open | 16,541.14 | 4,869.75 | | High | 16,683.37 | 5,019.20 | | Low | 16,064.09 | 4,854.75 | | Today's Cls | 16,127.98 | 4,872.00 | | Prev Cls | 16,123.15 | 4,865.90 | | Change | 4.83 | 6.10 | | % Change | 0.03 | 0.13 | | | | Market Indicators | | Top Movers (Group A) | | Company | Price
(Rs) | %
chg | | Gainers | | Indiabulls Real Estate | 568.10 | 8.70 | | MMTC | 23,550.00 | 8.14 | | Chambal Fertilisers | 55.30 | 7.38 | | Cairn India | 248.15 | 7.24 | | ABG Shipyard | 642.60 | 6.39 | | Losers | | Engineers India | 700.00 | -9.96 | | RCF | 63.75 | -7.94 | | India Infoline | 840.00 | -6.47 | | SAIL | 218.20 | -6.45 | | Tata Steel | 766.45 | -6.42 | | | Market Statistics | | - | BSE | NSE | | Advances | 1,271 | 517 | | Declines | 1,437 | 682 | | Unchanged | 55 | 26 | | Volume(Nos) | 40.62cr | 55.09cr | | | | | | Market Commentary | | | Profit taking trims Sensex gains | | The Sensex came off its early highs on selective profit taking and ended with marginal gains at 16,128. | | Even as major Asian indices like Nikkei, Hang Seng, Straits Times and Kospi managed to clock 1-2% gains, the Sensex failed to hold on to its early rally and closed | | | | way off its highs amid profit taking towards the closing hours. Riding on the back of yesterday's buoyant close and optimism in several international markets, the Sensex resumed 414 points higher at 16,541 and advanced sharply on sustained buying support to scale above 16,600 and touch an intra-day high of 16,683. After remaining above 16,500 for the entire first half, the Sensex came under the grip of profit taking and slipped below 16,100 to touch the day's low of 16,064, 59 points down. The Sensex finally ended the session with marginal gains of 5 points at 16,128, while the Nifty gained 6 points to close at 4,872. | | | Movers & Shakers | - Suven Life Sciences advanced on the report that the company has established second CNS Drug Discovery collaboration with Lilly.
- Strides Arcolab slipped despite receiving its second injectable ANDA approval for Tobramycin 40 mg/mL and USFDA approval for its Penicillin Sterile Facility in Bangalore.
- Voltas lost despite launching elegant new range of room air conditioners in 2008.
- Tata Communications inched up on the report that the company’s representative is to chair global wireless body-Wireless Broadband Alliance.
| | | |
Among the frontliners, Cipla soared 4.26% at Rs204, Grasim Industries rose 3.69% at Rs2,892, Reliance Energy added 3.19% at Rs1,328, ICICI Bank jumped 3.19% at Rs2.98, Bharti Airtel advanced 2.73% at Rs810.65, HDFC Bank gained 2.69% at Rs1,367.80, Ranbaxy moved up 2.44% at Rs464.35 and ONGC soared 2.02% at Rs1,014. However, Tisco dropped 6.42% at Rs766.45 while Hindalco declined 5.47% at Rs191.80 and DLF, SBI, Satyam Computers, Infosys, Tata Motors and Reliance Communications lost 3-4%.
The breadth of the market turned negative. Of the 2,763 stocks traded on the BSE, 1,437 stocks declined, 1,271 stocks advanced and 55 stocks ended unchanged. The BSE Realty Index was the lead performer and rose 1.23% at 8,327.75, while the BSE HC index gained 1.12% at 3,876.52.
Over 6.75 crore REC shares changed hands on the BSE followed by RNRL (2.21 crore shares), ISPAT Industries (1.85 crore shares), RPL (1.21 crore shares) and Nagarjuna Fertilisers (1.03 crore shares).
Valuewise, REC recorded a turnover of Rs825 crore followed by RNRL (Rs268 crore), RPL (Rs207 crore), RIL (Rs198 crore) and GSS America (Rs194 crore).
| | | | | | | | European Indices at 16:58 IST on 12-03-2008 | | | | Index | Level | Change (pts) | Change (%) | | FTSE 100 Index | 5793.10 | 102.70 | 1.80 | | CAC 40 Index | 4722.71 | 95.02 | 2.05 | | DAX Index | 6630.21 | 105.64 | 1.62 | | | | | | | | | | | Asian Indices at close on 12-03-2008 | | | | Index | Level | Change (pts) | Change (%) | | Nikkei 225 | 12861.13 | 202.85 | 1.60 | | Hang Seng Index | 23422.76 | 427.41 | 1.86 | | Kospi Index | 1658.83 | 17.35 | 1.06 | | Straits Times Index | 2917.94 | 57.09 | 2.00 | | Jakarta Composite Index | 2556.24 | 32.71 | 1.30 | | | | | | | | To know more about our products and services, click here. | | | | | | | “This document has been prepared by Sharekhan Ltd. This Document is subject to changes without prior notice and is intended only for the person or entity to which it is addressed to and may contain confidential and/or privileged material and is not for any type of circulation. Any review, retransmission, or any other use is prohibited. Kindly note that this document does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction.
Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. SHAREKHAN will not treat recipients as customers by virtue of their receiving this report.
The information contained herein is from publicly available data or other sources believed to be reliable. While we would endeavour to update the information herein on reasonable basis, SHAREKHAN, its subsidiaries and associated companies, their directors and employees (“SHAREKHAN and affiliates”) are under no obligation to update or keep the information current. Also, there may be regulatory, compliance, or other reasons that may prevent SHAREKHAN and affiliates from doing so. We do not represent that information contained herein is accurate or complete and it should not be relied upon as such. This document is prepared for assistance only and is not intended to be and must not alone betaken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. We do not undertake to advise you as to any change of our views. Affiliates of Sharekhan may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.
This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SHAREKHAN and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.
SHAREKHAN & affiliates may have used the information set forth herein before publication and may have positions in, may from time to time purchase or sell or may be materially interested in any of the securities mentioned or related securities. SHAREKHAN may from time to time solicit from, or perform investment banking, or other services for, any company mentioned herein. Without limiting any of the foregoing, in no event shall SHAREKHAN, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. Any comments or statements made herein are those of the analyst and do not necessarily reflect those of SHAREKHAN.” | To unsubscribe write to myaccount@sharekhan.com | |
